Biological Aging of Skeletal Muscles in Humans (BioAge)

Biological Aging of Skeletal Muscles in Humans, a Monocentric, Prospective Study

Aging affects almost all the tissues and physiological functions, and skeletal muscle is the most affected organ. The progressive decline of the weight and the muscular function linked to the aging contributes to the lack of autonomy and dependence, but also to an increase of the mortality risks. Sarcopenia is also a prevalent condition, because it is detected in 13-24% of 60 years old, and 50% of 80 years old and more.

However, strong inter-individual variations of this prevalence of sarcopenia exists. The key issue is to understand why the biological aging of the skeletal muscle is so different between people.

In this study, mechanisms involved in biological aging of the skeletal muscle in aging people (same chronological age) will be specified.

Study Overview

• Status: Completed
• Conditions: HEALTHY
• Intervention / Treatment: Other: Proof cohort : muscular assessment

Detailed Description

Aging affects almost all the tissues and physiological functions, and skeletal muscle is the most affected organ. The progressive decline of the weight and the muscular function linked to the aging contributes to the lack of autonomy and dependence, but also to an increase of the mortality risks. Sarcopenia is also a prevalent condition, because it is detected in 13-24% of 60 years old, and 50% of 80 years old and more.

However, strong inter-individual variations of this prevalence of sarcopenia exists. Some elderly (60 years old) reveal a biological aging of 80 years old, whereas 60 years old people reveal a biological aging of 60 years old. The key issue is to understand why the biological aging of the skeletal muscle is so different between people.

Previous sarcopenia studies in Humans did not really focus on chronological aging, they were all based on a comparison between young and old people. No study considered inter-individual modifications (biological aging) in sarcopenia. Furthermore, few studies were associated in the same study to "omic", histological, and epigenetic data, to obtain integrated point of view of Human Sarcopenia.

In this study, mechanisms involved in biological aging of the skeletal muscle in aging people (same chronological age) will be specified.

• Study Type: Observational
• Enrollment (Actual): 72

Contacts and Locations

Study Locations

• France
  • Saint Etienne, France, 42100
    • Chu Saint Etienne

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 80 years to 83 years (Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Patients are recruited in the Proof cohort (Barthélemy et al., 2007).

Description

Inclusion Criteria:

• Belonging to the Proof cohort
• Between 80 and 83 years old
• Informed consent signed
• Genetic analyses consent signed
• Subject affiliated or entitled to a social security scheme

Exclusion Criteria:

• Anti coagulative treatment
• Severe obesity (>35)
• All chronic pathology requiring a treatment
• Severe renal insufficiency (discovery less than 6 months)
• Abnormal coagulation appraisal
• Allergy to local anesthetics
• Installation of a prosthetic hip and / or knee in the last six months
• Senile dementia
• Refusal of genetic study

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Proof cohort : muscular assessment; Clinical examination : Body weight, BMI, cardiac frequency, muscular examination,...; Blood appraisal : glycaemia, lipidic appraisal, leptin, albumin, coagulation, metabolome and epigenetic tests,...; Urinary collection : metabolome tests; Maximal voluntary quadriceps strength (MVC); Checking muscle functional skills; Muscular biopsy	Other: Proof cohort : muscular assessment; Clinical examination, blood appraisal, urinary collection, MVC, checking muscle functional skills and muscular biopsy will be performed.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The area of type IIA fibers called vastus lateralis.	The primary endpoint is the cross sectional area (measured in µm2) of type IIA fibers from the vastus lateralis muscle biopsies.	Day 15

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire de Saint Etienne
• Collaborators: Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement; Ecole Nationale Superieure Lyon; Region Rhone Alpes
• Investigators: Principal Investigator: FEASSON Léonard, MD, Chu Saint Etienne

Publications and helpful links

General Publications

• Barthelemy JC, Pichot V, Dauphinot V, Celle S, Laurent B, Garcin A, Maudoux D, Kerleroux J, Lacour JR, Kossovsky M, Gaspoz JM, Roche F. Autonomic nervous system activity and decline as prognostic indicators of cardiovascular and cerebrovascular events: the 'PROOF' Study. Study design and population sample. Associations with sleep-related breathing disorders: the 'SYNAPSE' Study. Neuroepidemiology. 2007;29(1-2):18-28. doi: 10.1159/000108914.

Study record dates

Study Major Dates

• Study Start (Actual): February 18, 2016
• Primary Completion (Actual): January 20, 2017
• Study Completion (Actual): May 23, 2017

Study Registration Dates

• First Submitted: January 25, 2016
• First Submitted That Met QC Criteria: February 2, 2016
• First Posted (Estimate): February 5, 2016

Study Record Updates

• Last Update Posted (Actual): November 17, 2021
• Last Update Submitted That Met QC Criteria: November 16, 2021
• Last Verified: May 1, 2021

More Information

Terms related to this study

• Keywords: elderly; sarcopenia; muscle biopsy
• Other Study ID Numbers: 1508145; 2015-A01484-45 (Other Identifier: ANSM)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No